Sponsor

Access to Advanced Health Institute (AAHI)

Clinical research sponsor

Published trials9

Recruiting shown0

Roles2

SourceClinicalTrials.gov

Clinical trials

9 shown

Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment CompletionNCT02465216 · lead sponsor · 2015-06-01

COMPLETED

Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But UninfectedNCT06613789 · collaborator · 2027-03-30

NOT_YET_RECRUITING

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral TherapyNCT06680479 · collaborator · 2025-04-01

SUSPENDED

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + AlumNCT06267872 · collaborator · 2024-10-07

WITHDRAWN

A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, AdjuvantedNCT05983874 · collaborator · 2024-04-16

UNKNOWN

A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine CandidateNCT05863585 · collaborator · 2023-06-01

UNKNOWN

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIVNCT05781542 · collaborator · 2023-04-10

COMPLETED

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected AdultsNCT04927585 · collaborator · 2021-07-08

COMPLETED

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected AdultsNCT04177355 · collaborator · 2020-01-13

COMPLETED

Sponsor roles

collaborator8

lead sponsor1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.